Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA's Oncology Division Wants To Know About Your Pipeline, Not Just Your NDAs

Nov 20 2017

• By Derrick Gingery

FDA entrance sign 2016 — Richard Pazdur, director of FDA's Oncology Center of Excellence

Related Content

FDA Talent Hunt: Better To Recruit From Academia Than Industry?

Dec 14 2015

FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015

Apr 25 2016

US FDA Commits To Meeting With Complex ANDA Sponsors, Works Hard To Avoid It

Oct 24 2017

FDA's Pazdur Jumps Over To New 'Moonshot' Role

Jun 30 2016

PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?

Aug 26 2016

Related Companies

Merck & Co., Inc.

Genentech, Inc.

Roche Holding AG

Additional Topics

United States Review Pathway Regulation FDA Cancer BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.